Full-Time

Executive Director

Payer Marketing

Confirmed live in the last 24 hours

Axsome Therapeutics Inc

Axsome Therapeutics Inc

201-500 employees

Develops therapies for CNS disorders

Biotechnology
Healthcare

Compensation Overview

$270k - $305kAnnually

+ Annual Bonus + Equity

Senior, Expert

New York, NY, USA

On-site requirement of at least three days per week.

Category
General Marketing
Growth & Marketing
Required Skills
Market Research
Branding/Brand Strategy
Data Analysis
Requirements
  • Bachelor's degree in science, Business, Accounting, Finance, Mathematics, or related field required, MBA preferred
  • 12-15 years of Payer Marketing experience or other Market Access related activities
  • 12-15 years of Pharmaceutical Industry related experience
  • Ability to work onsite Monday, Tuesday & Thursday. *We are unable to consider candidates who are looking for fully remote roles*
Responsibilities
  • Lead the payer marketing team that will development and design of the Payer Value Proposition across multiple therapeutic areas, indications, and assets
  • Responsible for the creation of payer marketing narratives and resources that support overarching brand strategy and drive appropriate formulary access across Axsome’s in-market assets
  • Leverage data, internal and external insights, market events to craft a compelling narrative in the payer space ensuring patients have affordable access to Axsome’s innovative therapies
  • Work closely with the Account team and Market Research to leverage internally and externally generated insights that inform an impactful strategy
  • Partner with the HEOR team to deliver value messaging to payers that is substantiated by real world evidence generation / synthesis
  • Serve as point of contract with the Brand team, ensuring the payer point of view is represented and that payer access efforts support the overarching Brand Strategy
  • Manage, effectively and efficiently, multiple projects that require cross-functional buy-in across different indications and therapeutic areas
  • Manage agency efforts including scope, budget, and progress ensuring high quality projects are delivered in a timely and compliant fashion
Axsome Therapeutics Inc

Axsome Therapeutics Inc

View

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain to help regulate mood. This drug has shown positive results in clinical trials and has received FDA Breakthrough Therapy Designation, which helps speed up its approval process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and development. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.

Company Stage

IPO

Total Funding

$430.7M

Headquarters

New York City, New York

Founded

2012

Growth & Insights
Headcount

6 month growth

3%

1 year growth

3%

2 year growth

3%
Simplify Jobs

Simplify's Take

What believers are saying

  • The launch of Auvelity and the promising results of AXS-12 in Phase 3 trials indicate strong potential for revenue growth and market impact.
  • Axsome's strategic expansion of its sales force to support Auvelity's launch demonstrates its commitment to commercial success.
  • The appointment of experienced leaders like Dr. Sue Mahony to the board enhances Axsome's strategic direction and governance.

What critics are saying

  • The biopharmaceutical sector's inherent risks, including regulatory hurdles and clinical trial failures, could impact Axsome's progress.
  • High competition in the CNS disorder treatment market may challenge Axsome's ability to capture significant market share.

What makes Axsome Therapeutics Inc unique

  • Axsome Therapeutics focuses on CNS disorders with a strong emphasis on unmet medical needs, setting it apart from broader biopharmaceutical companies.
  • The FDA Breakthrough Therapy Designation for AXS-05 highlights its innovative approach and potential for rapid market entry.
  • Axsome's diversified pipeline, including treatments for MDD, TRD, Alzheimer's agitation, and narcolepsy, showcases its comprehensive strategy in CNS therapeutics.

Help us improve and share your feedback! Did you find this helpful?